Spinal Muscular Atrophy Treatment Market Size, Share & Trends Analysis Report By Type (Type 1, Type 2, Type 3, Type 4), By Treatment (Gene Therapy, Drug), By Route of Administration, By Region, And Segment Forecasts, 2025 - 2030
This report can be delivered to the clients within 2 Business Days
Spinal Muscular Atrophy Treatment Market Growth & Trends
The global spinal muscular atrophy treatment market size is expected treach USD 13.09 billion by 2030, registering a CAGR of 18.0% from 2025 t2030, according ta new study by Grand View Research Inc. This growth can be attributed tthe increasing product approval and launches. For instance, in August 2020, the Food and Drug Administration approved Evrysdi (risdiplam) developed by Genentech, Inc., for the treatment of pediatric patients aged twmonths and older with spinal muscular atrophy (SMA).
In addition, in May 2020, Novartis AG received conditional approval tits SMA candidate Zolgensma (onasemnogene abeparvovec) from the European Commission (EC) ttreat patients with SMA. It is only approved gene therapy in Europe. In March 2021, PTC Therapeutics, Inc., received marketing approval for Evrysdi (risdiplam) from the EMA for the treatment of patient with type1, 2, and 3 spinal muscular atrophy. Thus, increasing number of product approvals is expected tdrive the spinal muscular atrophy treatment market.
Novartis AG is supporting SMA patients by offering medicine at free of cost through global Managed Access Program (MAP). This program provides 100 doses of Zolgensma at free of charge teligible SMA patients across continents including North America, South America, Asia, Australia, Europe, and Africa. Thus, presence of such supportive programs for Zolgensma strengthens promotional activities and alsaid in generating revenue.
Global SMA newborn screening and easy access tdiagnostic tools should be included in routine approach. This would ensure early diagnosis and timely access ttreatment. For instance, in July 2021, a charlotte baby received a breakthrough gene therapy treatment for Spinal Muscular Atrophy (SMA) at UNC Medical Center in Chapel Hill, N.C., after diagnosis with spinal muscular atrophy through Early Check newborn screening program. Such screening programs are expected tboost early diagnosis and treatment of disease.
Moreover, there are several extensive research collaborations undertaken by pharmaceutical companies with research institutes for developing novel therapies for the treatment of spinal muscular atrophy patients. For instance, in March 2021, PTC Therapeutics, Inc., and The Spinal Muscular Atrophy Foundation entered intresearch collaboration tadvance scientific research and developing new treatment ttreat patients with SMA.
However, high costs associated with the treatment and low availability of participant for clinical trial purposes may restrain market growth over the forecast period. The high cost related tresearch and development of an orphan drug is a major factor of rising prices of product. For instance, the most commonly used drug Spinraza costs around USD 125,000 per injection and USD 750,000 annually. Furthermore, Zolgensma (AVXS-101) costs USD 2.1 million for one time treatment.
Spinal Muscular Atrophy Treatment Market Report Highlights
Spinal Muscular Atrophy Treatment Market Growth & Trends
The global spinal muscular atrophy treatment market size is expected treach USD 13.09 billion by 2030, registering a CAGR of 18.0% from 2025 t2030, according ta new study by Grand View Research Inc. This growth can be attributed tthe increasing product approval and launches. For instance, in August 2020, the Food and Drug Administration approved Evrysdi (risdiplam) developed by Genentech, Inc., for the treatment of pediatric patients aged twmonths and older with spinal muscular atrophy (SMA).
In addition, in May 2020, Novartis AG received conditional approval tits SMA candidate Zolgensma (onasemnogene abeparvovec) from the European Commission (EC) ttreat patients with SMA. It is only approved gene therapy in Europe. In March 2021, PTC Therapeutics, Inc., received marketing approval for Evrysdi (risdiplam) from the EMA for the treatment of patient with type1, 2, and 3 spinal muscular atrophy. Thus, increasing number of product approvals is expected tdrive the spinal muscular atrophy treatment market.
Novartis AG is supporting SMA patients by offering medicine at free of cost through global Managed Access Program (MAP). This program provides 100 doses of Zolgensma at free of charge teligible SMA patients across continents including North America, South America, Asia, Australia, Europe, and Africa. Thus, presence of such supportive programs for Zolgensma strengthens promotional activities and alsaid in generating revenue.
Global SMA newborn screening and easy access tdiagnostic tools should be included in routine approach. This would ensure early diagnosis and timely access ttreatment. For instance, in July 2021, a charlotte baby received a breakthrough gene therapy treatment for Spinal Muscular Atrophy (SMA) at UNC Medical Center in Chapel Hill, N.C., after diagnosis with spinal muscular atrophy through Early Check newborn screening program. Such screening programs are expected tboost early diagnosis and treatment of disease.
Moreover, there are several extensive research collaborations undertaken by pharmaceutical companies with research institutes for developing novel therapies for the treatment of spinal muscular atrophy patients. For instance, in March 2021, PTC Therapeutics, Inc., and The Spinal Muscular Atrophy Foundation entered intresearch collaboration tadvance scientific research and developing new treatment ttreat patients with SMA.
However, high costs associated with the treatment and low availability of participant for clinical trial purposes may restrain market growth over the forecast period. The high cost related tresearch and development of an orphan drug is a major factor of rising prices of product. For instance, the most commonly used drug Spinraza costs around USD 125,000 per injection and USD 750,000 annually. Furthermore, Zolgensma (AVXS-101) costs USD 2.1 million for one time treatment.
Spinal Muscular Atrophy Treatment Market Report Highlights
- By type, the type-1 segment held the largest market share in 2024 due thigher prevalence and wide availability of products for the treatment of patients with type-1 spinal muscular atrophy
- By treatment, the gene therapy segment is expected tbe the fastest growing segment over the forecast period due tincrease market penetration. Zolgensma is the only approved gene therapy in 37 countries ttreat patient with SMA
- By drug, the Spinraza segment dominated the market in 2024 due tpresence of supportive reimbursement policies and increasing awareness about products. Currently, Spinraza is applicable for full reimbursement in three European countries Italy, Norway, Netherlands
- By route of administration, the injection segment dominated the market in 2024 due thigh safety, efficacy, and tolerability associated with infusion drugs tSMA patients through this route of administration
- Asia Pacific is expected tbe the fastest growing region during the forecast period. The growth of region is attributable tthe entry of new products intthe region. For instance, in July 2021, F. Hoffmann-La Roche Ltd launched Evrysdi (risdiplam) for the treatment of patient with spinal muscular atrophy in India
CHAPTER 1. METHODOLOGY AND SCOPE
1.1. Market Segmentation & Scope
1.2. Segment Definitions
1.2.1. Type
1.2.2. Treatment
1.2.3. Route of Administration
1.3. Estimates and Forecast Timeline
1.4. Research Methodology
1.5. Information Procurement
1.5.1. Purchased Database
1.5.2. GVR’s Internal Database
1.5.3. Secondary Sources
1.5.4. Primary Research
1.6. Information Analysis
1.6.1. Data Analysis Models
1.7. Market Formulation & Data Visualization
1.8. Model Details
1.8.1. Commodity Flow Analysis
1.9. List of Secondary Sources
1.10. Objectives
CHAPTER 2. EXECUTIVE SUMMARY
2.1. Market Snapshot
2.2. Segment Snapshot
2.3. Competitive Landscape Snapshot
CHAPTER 3. SPINAL MUSCULAR ATROPHY TREATMENT MARKET VARIABLES, TRENDS, & SCOPE
3.1. Market Lineage Outlook
3.2. Market Dynamics
3.2.1. Market Driver Analysis
3.2.2. Market Restraint Analysis
3.3. Business Environment Analysis
3.3.1. Industry Analysis - Porter’s Five Forces Analysis
3.3.1.1. Supplier Power
3.3.1.2. Buyer Power
3.3.1.3. Substitution Threat
3.3.1.4. Threat of New Entrants
3.3.1.5. Competitive Rivalry
3.3.2. PESTLE Analysis
CHAPTER 4. SPINAL MUSCULAR ATROPHY TREATMENT MARKET: TYPE BUSINESS ANALYSIS
4.1. Type Market Share, 2024 & 2030
4.2. Type Segment Dashboard
4.3. Market Size & Forecasts and Trend Analysis, by Type, 2018 to 2030 (USD Billion)
4.4. Type
4.4.1. Type 1 Market, 2018 - 2030 (USD Billion)
4.5. Type
4.5.1. Type 2 Market, 2018 - 2030 (USD Billion)
4.6. Type
4.6.1. Type 3 Market, 2018 - 2030 (USD Billion)
4.7. Type
4.7.1. Type 4 Market, 2018 - 2030 (USD Billion)
CHAPTER 5. SPINAL MUSCULAR ATROPHY TREATMENT MARKET: TREATMENT BUSINESS ANALYSIS
5.1. Treatment Market Share, 2024 & 2030
5.2. Treatment Segment Dashboard
5.3. Market Size & Forecasts and Trend Analysis, by Treatment, 2018 to 2030 (USD Billion)
5.4. Gene Therapy
5.4.1. Gene Therapy Market, 2018 - 2030 (USD Billion)
5.5. Drug
5.5.1. Drug Market, 2018 - 2030 (USD Billion)
5.5.2. Spinraza
5.5.2.1. Spinraza Market, 2018 - 2030 (USD Billion)
5.5.3. Zolgensma (AVXS-101)
5.5.3.1. Zolgensma (AVXS-101) Market, 2018 - 2030 (USD Billion)
5.5.4. Evrysdi
5.5.4.1. Evrysdi Market, 2018 - 2030 (USD Billion)
5.5.5. Others
5.5.5.1. Others Market, 2018 - 2030 (USD Billion)
CHAPTER 6. SPINAL MUSCULAR ATROPHY TREATMENT MARKET: ROUTE OF ADMINISTRATION BUSINESS ANALYSIS
6.1. Route of Administration Market Share, 2024 & 2030
6.2. Route of Administration Segment Dashboard
6.3. Market Size & Forecasts and Trend Analysis, by Route of Administration, 2018 to 2030 (USD Billion)
6.4. Oral
6.4.1. Oral Market, 2018 - 2030 (USD Billion)
6.5. Injection
6.5.1. Injection Market, 2018 - 2030 (USD Billion)
CHAPTER 7. SPINAL MUSCULAR ATROPHY TREATMENT MARKET: REGIONAL ESTIMATES & TREND ANALYSIS
7.1. Regional Market Share Analysis, 2024 & 2030
7.2. Regional Market Dashboard
7.3. Market Size & Forecasts Trend Analysis, 2018 to 2030:
7.4. North America
7.4.1. North America Spinal Muscular Atrophy Treatment Market Estimates and Forecasts, by Country, 2018 - 2030 (USD Billion)
7.4.2. U.S.
7.4.2.1. Key Country Dynamics
7.4.2.2. Regulatory Framework
7.4.2.3. Competitive Insights
7.4.2.4. U.S. Spinal Muscular Atrophy Treatment Market Estimates and Forecasts, 2018 - 2030 (USD Billion)
7.4.3. Canada
7.4.3.1. Key Country Dynamics
7.4.3.2. Regulatory Framework
7.4.3.3. Competitive Insights
7.4.3.4. Canada Spinal Muscular Atrophy Treatment Market Estimates and Forecasts, 2018 - 2030 (USD Billion)
7.4.4. Mexico
7.4.4.1. Key Country Dynamics
7.4.4.2. Regulatory Framework
7.4.4.3. Competitive Insights
7.4.4.4. Mexico Spinal Muscular Atrophy Treatment Market Estimates and Forecasts, 2018 - 2030 (USD Billion)
7.5. Europe
7.5.1. Europe Spinal Muscular Atrophy Treatment Market Estimates and Forecasts, by Country, 2018 - 2030 (USD Billion)
7.5.2. UK
7.5.2.1. Key Country Dynamics
7.5.2.2. Regulatory Framework
7.5.2.3. Competitive Insights
7.5.2.4. UK Spinal Muscular Atrophy Treatment Market Estimates and Forecasts, 2018 - 2030 (USD Billion)
7.5.3. Germany
7.5.3.1. Key Country Dynamics
7.5.3.2. Regulatory Framework
7.5.3.3. Competitive Insights
7.5.3.4. Germany Spinal Muscular Atrophy Treatment Market Estimates and Forecasts, 2018 - 2030 (USD Billion)
7.5.4. France
7.5.4.1. Key Country Dynamics
7.5.4.2. Regulatory Framework
7.5.4.3. Competitive Insights
7.5.4.4. France Spinal Muscular Atrophy Treatment Market Estimates and Forecasts, 2018 - 2030 (USD Billion)
7.5.5. Italy
7.5.5.1. Key Country Dynamics
7.5.5.2. Regulatory Framework
7.5.5.3. Competitive Insights
7.5.5.4. Italy Spinal Muscular Atrophy Treatment Market Estimates and Forecasts, 2018 - 2030 (USD Billion)
7.5.6. Spain
7.5.6.1. Key Country Dynamics
7.5.6.2. Regulatory Framework
7.5.6.3. Competitive Insights
7.5.6.4. Spain Spinal Muscular Atrophy Treatment Market Estimates and Forecasts, 2018 - 2030 (USD Billion)
7.5.7. Norway
7.5.7.1. Key Country Dynamics
7.5.7.2. Regulatory Framework
7.5.7.3. Competitive Insights
7.5.7.4. Norway Spinal Muscular Atrophy Treatment Market Estimates and Forecasts, 2018 - 2030 (USD Billion)
7.5.8. Denmark
7.5.8.1. Key Country Dynamics
7.5.8.2. Regulatory Framework
7.5.8.3. Competitive Insights
7.5.8.4. Denmark Spinal Muscular Atrophy Treatment Market Estimates and Forecasts, 2018 - 2030 (USD Billion)
7.5.9. Sweden
7.5.9.1. Key Country Dynamics
7.5.9.2. Regulatory Framework
7.5.9.3. Competitive Insights
7.5.9.4. Sweden Spinal Muscular Atrophy Treatment Market Estimates and Forecasts, by Country, 2018 - 2030 (USD Billion)
7.6. Asia Pacific
7.6.1. Asia Pacific Spinal Muscular Atrophy Treatment Market Estimates and Forecasts, 2018 - 2030 (USD Billion)
7.6.2. Japan
7.6.2.1. Key Country Dynamics
7.6.2.2. Regulatory Framework
7.6.2.3. Competitive Insights
7.6.2.4. Japan Spinal Muscular Atrophy Treatment Market Estimates and Forecasts, 2018 - 2030 (USD Billion)
7.6.3. China
7.6.3.1. Key Country Dynamics
7.6.3.2. Regulatory Framework
7.6.3.3. Competitive Insights
7.6.3.4. China Spinal Muscular Atrophy Treatment Market Estimates and Forecasts, 2018 - 2030 (USD Billion)
7.6.4. India
7.6.4.1. Key Country Dynamics
7.6.4.2. Regulatory Framework
7.6.4.3. Competitive Insights
7.6.4.4. India Spinal Muscular Atrophy Treatment Market Estimates and Forecasts, 2018 - 2030 (USD Billion)
7.6.5. South Korea
7.6.5.1. Key Country Dynamics
7.6.5.2. Regulatory Framework
7.6.5.3. Competitive Insights
7.6.5.4. South Korea Spinal Muscular Atrophy Treatment Market Estimates and Forecasts, 2018 - 2030 (USD Billion)
7.6.6. Australia
7.6.6.1. Key Country Dynamics
7.6.6.2. Regulatory Framework
7.6.6.3. Competitive Insights
7.6.6.4. Australia Spinal Muscular Atrophy Treatment Market Estimates and Forecasts, 2018 - 2030 (USD Billion)
7.6.7. Thailand
7.6.7.1. Key Country Dynamics
7.6.7.2. Regulatory Framework
7.6.7.3. Competitive Insights
7.6.7.4. Thailand Spinal Muscular Atrophy Treatment Market Estimates and Forecasts, 2018 - 2030 (USD Billion)
7.7. Latin America
7.7.1. Latin America Spinal Muscular Atrophy Treatment Market Estimates and Forecasts, by Country, 2018 - 2030 (USD Billion)
7.7.2. Brazil
7.7.2.1. Key Country Dynamics
7.7.2.2. Regulatory Framework
7.7.2.3. Competitive Insights
7.7.2.4. Brazil Spinal Muscular Atrophy Treatment Market Estimates and Forecasts, 2018 - 2030 (USD Billion)
7.7.3. Argentina
7.7.3.1. Key Country Dynamics
7.7.3.2. Regulatory Framework
7.7.3.3. Competitive Insights
7.7.3.4. Argentina Spinal Muscular Atrophy Treatment Market Estimates and Forecasts, 2018 - 2030 (USD Billion)
7.8. MEA
7.8.1. MEA Spinal Muscular Atrophy Treatment Market Estimates and Forecasts, by Country, 2018 - 2030 (USD Billion)
7.8.2. South Africa
7.8.2.1. Key Country Dynamics
7.8.2.2. Regulatory Framework
7.8.2.3. Competitive Insights
7.8.2.4. South Africa Spinal Muscular Atrophy Treatment Market Estimates and Forecasts, 2018 - 2030 (USD Billion)
7.8.3. Saudi Arabia
7.8.3.1. Key Country Dynamics
7.8.3.2. Regulatory Framework
7.8.3.3. Competitive Insights
7.8.3.4. Saudi Arabia Spinal Muscular Atrophy Treatment Market Estimates and Forecasts, 2018 - 2030 (USD Billion)
7.8.4. UAE
7.8.4.1. Key Country Dynamics
7.8.4.2. Regulatory Framework
7.8.4.3. Competitive Insights
7.8.4.4. UAE Spinal Muscular Atrophy Treatment Market Estimates and Forecasts, 2018 - 2030 (USD Billion)
7.8.5. Kuwait
7.8.5.1. Key Country Dynamics
7.8.5.2. Regulatory Framework
7.8.5.3. Competitive Insights
7.8.5.4. Kuwait Spinal Muscular Atrophy Treatment Market Estimates and Forecasts, 2018 - 2030 (USD Billion)
CHAPTER 8. COMPETITIVE LANDSCAPE
8.1. Participant Overview
8.2. Company Market Position Analysis
8.3. Company Categorization
8.4. Strategy Mapping
8.5. Company Profiles/Listing
8.5.1. Biogen
8.5.1.1. Overview
8.5.1.2. Financial Performance
8.5.1.3. Product Benchmarking
8.5.1.4. Strategic Initiatives
8.5.2. Novartis AG
8.5.2.1. Overview
8.5.2.2. Financial Performance
8.5.2.3. Product Benchmarking
8.5.2.4. Strategic Initiatives
8.5.3. Pfizer Inc.
8.5.3.1. Overview
8.5.3.2. Financial Performance
8.5.3.3. Product Benchmarking
8.5.3.4. Strategic Initiatives
8.5.4. Ionis Pharmaceuticals
8.5.4.1. Overview
8.5.4.2. Financial Performance
8.5.4.3. Product Benchmarking
8.5.4.4. Strategic Initiatives
8.5.5. Biohaven, Ltd.
8.5.5.1. Overview
8.5.5.2. Financial Performance
8.5.5.3. Product Benchmarking
8.5.5.4. Strategic Initiatives
8.5.6. F. Hoffmann-La Roche Ltd
8.5.6.1. Overview
8.5.6.2. Financial Performance
8.5.6.3. Product Benchmarking
8.5.6.4. Strategic Initiatives
8.5.7. Cytokinetics
8.5.7.1. Overview
8.5.7.2. Financial Performance
8.5.7.3. Product Benchmarking
8.5.7.4. Strategic Initiatives
8.5.8. Scholar Rock, Inc.
8.5.8.1. Overview
8.5.8.2. Financial Performance
8.5.8.3. Product Benchmarking
8.5.8.4. Strategic Initiatives
8.5.9. PTC Therapeutics
8.5.9.1. Overview
8.5.9.2. Financial Performance
8.5.9.3. Product Benchmarking
8.5.9.4. Strategic Initiatives
8.5.10. NMD PHARMA A/S
8.5.10.1. Overview
8.5.10.2. Financial Performance
8.5.10.3. Product Benchmarking
8.5.10.4. Strategic Initiatives
1.1. Market Segmentation & Scope
1.2. Segment Definitions
1.2.1. Type
1.2.2. Treatment
1.2.3. Route of Administration
1.3. Estimates and Forecast Timeline
1.4. Research Methodology
1.5. Information Procurement
1.5.1. Purchased Database
1.5.2. GVR’s Internal Database
1.5.3. Secondary Sources
1.5.4. Primary Research
1.6. Information Analysis
1.6.1. Data Analysis Models
1.7. Market Formulation & Data Visualization
1.8. Model Details
1.8.1. Commodity Flow Analysis
1.9. List of Secondary Sources
1.10. Objectives
CHAPTER 2. EXECUTIVE SUMMARY
2.1. Market Snapshot
2.2. Segment Snapshot
2.3. Competitive Landscape Snapshot
CHAPTER 3. SPINAL MUSCULAR ATROPHY TREATMENT MARKET VARIABLES, TRENDS, & SCOPE
3.1. Market Lineage Outlook
3.2. Market Dynamics
3.2.1. Market Driver Analysis
3.2.2. Market Restraint Analysis
3.3. Business Environment Analysis
3.3.1. Industry Analysis - Porter’s Five Forces Analysis
3.3.1.1. Supplier Power
3.3.1.2. Buyer Power
3.3.1.3. Substitution Threat
3.3.1.4. Threat of New Entrants
3.3.1.5. Competitive Rivalry
3.3.2. PESTLE Analysis
CHAPTER 4. SPINAL MUSCULAR ATROPHY TREATMENT MARKET: TYPE BUSINESS ANALYSIS
4.1. Type Market Share, 2024 & 2030
4.2. Type Segment Dashboard
4.3. Market Size & Forecasts and Trend Analysis, by Type, 2018 to 2030 (USD Billion)
4.4. Type
4.4.1. Type 1 Market, 2018 - 2030 (USD Billion)
4.5. Type
4.5.1. Type 2 Market, 2018 - 2030 (USD Billion)
4.6. Type
4.6.1. Type 3 Market, 2018 - 2030 (USD Billion)
4.7. Type
4.7.1. Type 4 Market, 2018 - 2030 (USD Billion)
CHAPTER 5. SPINAL MUSCULAR ATROPHY TREATMENT MARKET: TREATMENT BUSINESS ANALYSIS
5.1. Treatment Market Share, 2024 & 2030
5.2. Treatment Segment Dashboard
5.3. Market Size & Forecasts and Trend Analysis, by Treatment, 2018 to 2030 (USD Billion)
5.4. Gene Therapy
5.4.1. Gene Therapy Market, 2018 - 2030 (USD Billion)
5.5. Drug
5.5.1. Drug Market, 2018 - 2030 (USD Billion)
5.5.2. Spinraza
5.5.2.1. Spinraza Market, 2018 - 2030 (USD Billion)
5.5.3. Zolgensma (AVXS-101)
5.5.3.1. Zolgensma (AVXS-101) Market, 2018 - 2030 (USD Billion)
5.5.4. Evrysdi
5.5.4.1. Evrysdi Market, 2018 - 2030 (USD Billion)
5.5.5. Others
5.5.5.1. Others Market, 2018 - 2030 (USD Billion)
CHAPTER 6. SPINAL MUSCULAR ATROPHY TREATMENT MARKET: ROUTE OF ADMINISTRATION BUSINESS ANALYSIS
6.1. Route of Administration Market Share, 2024 & 2030
6.2. Route of Administration Segment Dashboard
6.3. Market Size & Forecasts and Trend Analysis, by Route of Administration, 2018 to 2030 (USD Billion)
6.4. Oral
6.4.1. Oral Market, 2018 - 2030 (USD Billion)
6.5. Injection
6.5.1. Injection Market, 2018 - 2030 (USD Billion)
CHAPTER 7. SPINAL MUSCULAR ATROPHY TREATMENT MARKET: REGIONAL ESTIMATES & TREND ANALYSIS
7.1. Regional Market Share Analysis, 2024 & 2030
7.2. Regional Market Dashboard
7.3. Market Size & Forecasts Trend Analysis, 2018 to 2030:
7.4. North America
7.4.1. North America Spinal Muscular Atrophy Treatment Market Estimates and Forecasts, by Country, 2018 - 2030 (USD Billion)
7.4.2. U.S.
7.4.2.1. Key Country Dynamics
7.4.2.2. Regulatory Framework
7.4.2.3. Competitive Insights
7.4.2.4. U.S. Spinal Muscular Atrophy Treatment Market Estimates and Forecasts, 2018 - 2030 (USD Billion)
7.4.3. Canada
7.4.3.1. Key Country Dynamics
7.4.3.2. Regulatory Framework
7.4.3.3. Competitive Insights
7.4.3.4. Canada Spinal Muscular Atrophy Treatment Market Estimates and Forecasts, 2018 - 2030 (USD Billion)
7.4.4. Mexico
7.4.4.1. Key Country Dynamics
7.4.4.2. Regulatory Framework
7.4.4.3. Competitive Insights
7.4.4.4. Mexico Spinal Muscular Atrophy Treatment Market Estimates and Forecasts, 2018 - 2030 (USD Billion)
7.5. Europe
7.5.1. Europe Spinal Muscular Atrophy Treatment Market Estimates and Forecasts, by Country, 2018 - 2030 (USD Billion)
7.5.2. UK
7.5.2.1. Key Country Dynamics
7.5.2.2. Regulatory Framework
7.5.2.3. Competitive Insights
7.5.2.4. UK Spinal Muscular Atrophy Treatment Market Estimates and Forecasts, 2018 - 2030 (USD Billion)
7.5.3. Germany
7.5.3.1. Key Country Dynamics
7.5.3.2. Regulatory Framework
7.5.3.3. Competitive Insights
7.5.3.4. Germany Spinal Muscular Atrophy Treatment Market Estimates and Forecasts, 2018 - 2030 (USD Billion)
7.5.4. France
7.5.4.1. Key Country Dynamics
7.5.4.2. Regulatory Framework
7.5.4.3. Competitive Insights
7.5.4.4. France Spinal Muscular Atrophy Treatment Market Estimates and Forecasts, 2018 - 2030 (USD Billion)
7.5.5. Italy
7.5.5.1. Key Country Dynamics
7.5.5.2. Regulatory Framework
7.5.5.3. Competitive Insights
7.5.5.4. Italy Spinal Muscular Atrophy Treatment Market Estimates and Forecasts, 2018 - 2030 (USD Billion)
7.5.6. Spain
7.5.6.1. Key Country Dynamics
7.5.6.2. Regulatory Framework
7.5.6.3. Competitive Insights
7.5.6.4. Spain Spinal Muscular Atrophy Treatment Market Estimates and Forecasts, 2018 - 2030 (USD Billion)
7.5.7. Norway
7.5.7.1. Key Country Dynamics
7.5.7.2. Regulatory Framework
7.5.7.3. Competitive Insights
7.5.7.4. Norway Spinal Muscular Atrophy Treatment Market Estimates and Forecasts, 2018 - 2030 (USD Billion)
7.5.8. Denmark
7.5.8.1. Key Country Dynamics
7.5.8.2. Regulatory Framework
7.5.8.3. Competitive Insights
7.5.8.4. Denmark Spinal Muscular Atrophy Treatment Market Estimates and Forecasts, 2018 - 2030 (USD Billion)
7.5.9. Sweden
7.5.9.1. Key Country Dynamics
7.5.9.2. Regulatory Framework
7.5.9.3. Competitive Insights
7.5.9.4. Sweden Spinal Muscular Atrophy Treatment Market Estimates and Forecasts, by Country, 2018 - 2030 (USD Billion)
7.6. Asia Pacific
7.6.1. Asia Pacific Spinal Muscular Atrophy Treatment Market Estimates and Forecasts, 2018 - 2030 (USD Billion)
7.6.2. Japan
7.6.2.1. Key Country Dynamics
7.6.2.2. Regulatory Framework
7.6.2.3. Competitive Insights
7.6.2.4. Japan Spinal Muscular Atrophy Treatment Market Estimates and Forecasts, 2018 - 2030 (USD Billion)
7.6.3. China
7.6.3.1. Key Country Dynamics
7.6.3.2. Regulatory Framework
7.6.3.3. Competitive Insights
7.6.3.4. China Spinal Muscular Atrophy Treatment Market Estimates and Forecasts, 2018 - 2030 (USD Billion)
7.6.4. India
7.6.4.1. Key Country Dynamics
7.6.4.2. Regulatory Framework
7.6.4.3. Competitive Insights
7.6.4.4. India Spinal Muscular Atrophy Treatment Market Estimates and Forecasts, 2018 - 2030 (USD Billion)
7.6.5. South Korea
7.6.5.1. Key Country Dynamics
7.6.5.2. Regulatory Framework
7.6.5.3. Competitive Insights
7.6.5.4. South Korea Spinal Muscular Atrophy Treatment Market Estimates and Forecasts, 2018 - 2030 (USD Billion)
7.6.6. Australia
7.6.6.1. Key Country Dynamics
7.6.6.2. Regulatory Framework
7.6.6.3. Competitive Insights
7.6.6.4. Australia Spinal Muscular Atrophy Treatment Market Estimates and Forecasts, 2018 - 2030 (USD Billion)
7.6.7. Thailand
7.6.7.1. Key Country Dynamics
7.6.7.2. Regulatory Framework
7.6.7.3. Competitive Insights
7.6.7.4. Thailand Spinal Muscular Atrophy Treatment Market Estimates and Forecasts, 2018 - 2030 (USD Billion)
7.7. Latin America
7.7.1. Latin America Spinal Muscular Atrophy Treatment Market Estimates and Forecasts, by Country, 2018 - 2030 (USD Billion)
7.7.2. Brazil
7.7.2.1. Key Country Dynamics
7.7.2.2. Regulatory Framework
7.7.2.3. Competitive Insights
7.7.2.4. Brazil Spinal Muscular Atrophy Treatment Market Estimates and Forecasts, 2018 - 2030 (USD Billion)
7.7.3. Argentina
7.7.3.1. Key Country Dynamics
7.7.3.2. Regulatory Framework
7.7.3.3. Competitive Insights
7.7.3.4. Argentina Spinal Muscular Atrophy Treatment Market Estimates and Forecasts, 2018 - 2030 (USD Billion)
7.8. MEA
7.8.1. MEA Spinal Muscular Atrophy Treatment Market Estimates and Forecasts, by Country, 2018 - 2030 (USD Billion)
7.8.2. South Africa
7.8.2.1. Key Country Dynamics
7.8.2.2. Regulatory Framework
7.8.2.3. Competitive Insights
7.8.2.4. South Africa Spinal Muscular Atrophy Treatment Market Estimates and Forecasts, 2018 - 2030 (USD Billion)
7.8.3. Saudi Arabia
7.8.3.1. Key Country Dynamics
7.8.3.2. Regulatory Framework
7.8.3.3. Competitive Insights
7.8.3.4. Saudi Arabia Spinal Muscular Atrophy Treatment Market Estimates and Forecasts, 2018 - 2030 (USD Billion)
7.8.4. UAE
7.8.4.1. Key Country Dynamics
7.8.4.2. Regulatory Framework
7.8.4.3. Competitive Insights
7.8.4.4. UAE Spinal Muscular Atrophy Treatment Market Estimates and Forecasts, 2018 - 2030 (USD Billion)
7.8.5. Kuwait
7.8.5.1. Key Country Dynamics
7.8.5.2. Regulatory Framework
7.8.5.3. Competitive Insights
7.8.5.4. Kuwait Spinal Muscular Atrophy Treatment Market Estimates and Forecasts, 2018 - 2030 (USD Billion)
CHAPTER 8. COMPETITIVE LANDSCAPE
8.1. Participant Overview
8.2. Company Market Position Analysis
8.3. Company Categorization
8.4. Strategy Mapping
8.5. Company Profiles/Listing
8.5.1. Biogen
8.5.1.1. Overview
8.5.1.2. Financial Performance
8.5.1.3. Product Benchmarking
8.5.1.4. Strategic Initiatives
8.5.2. Novartis AG
8.5.2.1. Overview
8.5.2.2. Financial Performance
8.5.2.3. Product Benchmarking
8.5.2.4. Strategic Initiatives
8.5.3. Pfizer Inc.
8.5.3.1. Overview
8.5.3.2. Financial Performance
8.5.3.3. Product Benchmarking
8.5.3.4. Strategic Initiatives
8.5.4. Ionis Pharmaceuticals
8.5.4.1. Overview
8.5.4.2. Financial Performance
8.5.4.3. Product Benchmarking
8.5.4.4. Strategic Initiatives
8.5.5. Biohaven, Ltd.
8.5.5.1. Overview
8.5.5.2. Financial Performance
8.5.5.3. Product Benchmarking
8.5.5.4. Strategic Initiatives
8.5.6. F. Hoffmann-La Roche Ltd
8.5.6.1. Overview
8.5.6.2. Financial Performance
8.5.6.3. Product Benchmarking
8.5.6.4. Strategic Initiatives
8.5.7. Cytokinetics
8.5.7.1. Overview
8.5.7.2. Financial Performance
8.5.7.3. Product Benchmarking
8.5.7.4. Strategic Initiatives
8.5.8. Scholar Rock, Inc.
8.5.8.1. Overview
8.5.8.2. Financial Performance
8.5.8.3. Product Benchmarking
8.5.8.4. Strategic Initiatives
8.5.9. PTC Therapeutics
8.5.9.1. Overview
8.5.9.2. Financial Performance
8.5.9.3. Product Benchmarking
8.5.9.4. Strategic Initiatives
8.5.10. NMD PHARMA A/S
8.5.10.1. Overview
8.5.10.2. Financial Performance
8.5.10.3. Product Benchmarking
8.5.10.4. Strategic Initiatives
